跳至主要内容
临床试验/CTRI/2012/05/002672
CTRI/2012/05/002672已完成2 期

An Open Labeled, Randomized, Prospective, Multi-center, Phase II, Clinical Study to Evaluate Comparative Efficacy and Safety of Seven Different Topical Formulations in Subjects Suffering from Osteoarthritis of Knee(s) - NI

Emami Limited0 个研究点目标入组 210 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
Emami Limited
入组人数
210

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Symptoms of osteoarthritis in one or both knee joints for a minimum of six months and maximum for five years
  • History of knee pain due to osteoarthritis requiring the use of NSAIDs, Acetaminophen, or another analgesic agent on a regular basis (greater than or equal to three days per week) for at least six months before the screening visit
  • OA confirmed by radiographs and diagnosed according to ACR diagnostic Criteria (clinical and radiological) for the osteoarthritis of the knee(s)
  • Subjects may take tab paracetamol (Less than of equal to 2g per day) for breakthrough pain
  • Subjects not having knee joint deformity
  • Subjects signing written informed consent and ready to comply with the protocol requirements
  • Subjects with pain VAS reater than 40 mm on weight bearing activities

排除标准

  • Rheumatoid arthritis, gout, pseudo gout, inflammatory arthritis, Pagets disease of bone, chronic pain syndrome, fibromyalgia, or another major joint disease
  • History of surgery, including arthroscopy, or major trauma to the study joint in the previous six months before the screening visit
  • Subjects requiring knee arthroplasty within 6 months of screening or anticipating any need for a surgical procedure on the index joint during the study
  • Signs of clinically important active inflammation of the study knee joint including redness, warmth and/or a large, bulging effusion with the loss of normal contour at the screening and/or baseline visits
  • Use of any analgesics except the study medication or paracetamol;
  • Use of systemic corticosteroids within 2 months of screening, or intra-articular viscosupplementation within the past 3 months
  • Use of any other investigational drug within 1 month prior to randomization;
  • Subjects having diabetes mellitus, tuberculosis, HIV, Ischemic Heart Disease
  • Known other major medical or surgical disease;
  • Pregnancy & Lactation.
  • Known hypersensitivity to ingredients used in study drug.

研究者

发起方
Emami Limited

相似试验

招募中
3 期
A clinical study to assess efficacy and safety of Febuxostat ER Tablet versus Febuxostat IR Tablet
CTRI/2024/01/061844AKUMS DRUGS PHARMACEUTICALS LTD
进行中(未招募)
1 期
A PROSPECTIVE, OPEN-LABEL, NON-RANDOMIZED, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF VORICONAZOLE AS PRIMARY THERAPY FOR TREATMENT OF INVASIVE ASPERGILLOSIS AND MOLDS SUCH AS SCEDOSPORIUM OR FUSARIUM SPECIES IN PEDIATRIC PATIENTSTreatment of proven or probable invasive aspergillosis (IA) and rare molds such asScedosporium or Fusarium species.MedDRA version: 9.1Level: LLTClassification code 10003488Term: AspergillosisMedDRA version: 9.1Level: LLTClassification code 10051919Term: Fusarium infectionMedDRA version: 9.1Level: LLTClassification code 10059045Term: Scedosporium infection
EUCTR2008-005275-10-HUPfizer Inc, 235 East 42nd Street, New York, NY 1001731
进行中(未招募)
不适用
A PROSPECTIVE, OPEN-LABEL, NON-RANDOMIZED, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF VORICONAZOLE AS PRIMARY THERAPY FOR TREATMENT OF INVASIVE ASPERGILLOSIS AND MOLDS SUCH AS SCEDOSPORIUM OR FUSARIUM SPECIES IN PEDIATRIC PATIENTS
EUCTR2008-005275-10-BGPfizer Inc, 235 East 42nd Street, New York, NY 1001736
进行中(未招募)
不适用
A prospective, Open-Label, Non-randomized, Multi-Center Study to Investigate the Safety and Tolerability of Voriconazole as Primary Therapy for Treatment of Invasive Aspergillosis and Molds such as Scedosporium or Fusarium Species in Pediatric PatientsTreatment of proven or probable invasive aspergillosis (IA) and rare molds such as Scedosporium or Fusarium species.MedDRA version: 14.1Level: PTClassification code 10003488Term: AspergillosisSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: PTClassification code 10059045Term: Scedosporium infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: PTClassification code 10051919Term: Fusarium infectionSystem Organ Class: 10021881 - Infections and infestations
EUCTR2008-005275-10-Outside-EU/EEAPfizer Inc, 235 East 42nd Street, New York, NY 1001736
进行中(未招募)
不适用
A PROSPECTIVE, OPEN-LABEL, NON-RANDOMIZED, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF VORICONAZOLE AS PRIMARY THERAPY FOR TREATMENT OF INVASIVE ASPERGILLOSIS AND MOLDS SUCH AS SCEDOSPORIUM OR FUSARIUM SPECIES IN PEDIATRIC PATIENTSTreatment of proven or probable invasive aspergillosis (IA) and rare molds such asScedosporium or Fusarium species.MedDRA version: 9.1Level: LLTClassification code 10003488Term: AspergillosisMedDRA version: 9.1Level: LLTClassification code 10051919Term: Fusarium infectionMedDRA version: 9.1Level: LLTClassification code 10059045Term: Scedosporium infection
EUCTR2008-005275-10-CZPfizer Inc.36